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I N RENAL transplant recipients, sirolimus has been 
studied extensively in combination with cyclosporine,l 
but relatively few published studies have looked at the 
combination of sirolimus and tacrolimus?-S We performed 
a pilot trial of tacrolimus, sirolimus, and steroids, without 
antibody induction and with protocol biopsies, to look at 
the safety and efficacy of this combination. This report 
describes the early outcomes in the first 30 patients entered 
into the trial. 
PATIENTS AND METHODS 
Thirty adults undergoing their first kidney transplantation alone, 
either with a cadaver (n = 20) or a living donor (n = 10) kidney, 
were entered into the trial. The mean recipient age was 50.7 :: 12.5 
years (range 25.5 to 73.6). Patients undergoing previous extrarenal 
transplantation were excluded. 
Immunosuppression consisted of tacrolimus (0.05 mg/kg PO) 
preoperatively, and (0.05 mglkg PO BID) postoperatively. Target 
levels were 8 to 10 ng/mL for the first 3 months and 5 to 7 ng/mL 
thereafter. The first five patients entered into the trial received 
siTOlimus (6 mg PO) preoperatively and (2 mg (n = 4) or 5 mg (n 
= 1) PO qd) postoperatively. The remaining 25 patients received 
sirolimus (15 mg PO) preoperatively and (5 mg po qd) postoper-
atively (one patient developed immediate thrombocytopenia and 
did not receive any sirolimus postoperatively). Target sirolimus 
levels were 6 to 10 ng/mL for the first 3 months and 5 to 7 ng/mL 
thereafter. All patients received 1000 mg IV methylprednisolone 
intraoperatively and a f)-day recycle from 200 --> 20 mg/day of 
either intravenous methylprednisolone or oral prednisone. Further 
steroid tapering was individualized but generally followed our 
previously described protocols. 6 Antibody induction was not used. 
The mean cold ischemia time for the 20 cadaver cases was 26.2 
c: 6.1 hours. The mean number of HLA matches and mismatches 
was 2.5 2: 1.1 and 2.8 = 1.2, respectively. 
Protocol biopsies were performed at approximately 1 week, 1 
month, and 1 year after transplantation. 
TI1IS pilot trial was approved by the Institutional Review Board 
of the University of Pittsburgh. and patients signed informed 
cunsent to participate. 
RESULTS 
The mean follow up was 7.7 ::!: 3.8 months. Patient survival 
was 97%: one patient died 5.7 months after transplantation 
of uterine carcinoma that was unknowingly present at the 
time of transplantation. Graft survival was 93%; one other 
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kidney was lost to thrombosis immediately after transplan-
tation because of a hypercoagulable state .in the recipient. 
The mean serum creatinine at most recent follow-up was 
1.8::!: 0.7 mgJdL. The mean serum cholesterol was 192 2: 47 
mg/dL; the mean serum triglyceride level was 245 :: 142 
mg/dL. The mean platelet count was 218,000 2: 56,000. 
In the five patients receiving 6 mg of sirolimus preoper-
atively, four had undetectable levels, and three had clinical 
(n = 2) or subclinical (n = 1) evidence of Banff lA or worse 
rejection. In the 25 patients receiving 15 mg of sirolimus 
preoperatively, the incidence of clinical Banff lA or worse 
rejection was 16%; the incidence of subclinical Banff lA or 
worst tubulitis was 12%. The incidence of borderline 
changes, either clinical or subclinical, was 24%. The inci-
dence of steroid-resistant rejection was 4%. 
The mean tacrolimus levels were 10.2 2: 5.7 mg/mL at 1 
week and 14.9 2: 5.7 mg/mL at 1 month. The mean 
sirolimus levels in the 25 patients receiving 15 mg preoper-
atively were 4.7 ::!: 1.7 ng/mL at 1 week and 7.4 2: 4.2 ng/mL 
at 1 month. Nine (30%) patients discontinued sirolimus; 
four because of thrombocytopenia and five for other rea-
sons. The initial and final incidences of posttransplant 
diabetes mellitus (PTDM) were 24% and 10%. The inci-
dence of delayed graft function was 24%. One sulfa-allergic 
patient developed pneumocystis carinii pneumonia on dap-
sone prophylaxis. Although she required transfer to the 
intensive care unit, intubation, and assisted ventilation, she 
eventually made a complete recovery and kept her allograft. 
DISCUSSION 
This nonrandomizeJ pilot trial represented both an attempt 
to study the safety and efficacy of the combination of 
low-dose tacrolimus and sirolimus and an opportunity to 
obtain some experience using the combination of the two 
agents prior to performing a randomized trial. The combi-
nation seemed reasonably safe and efficacious. Among the 
lessons we learned was that the low initial dosages of 
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sirolimus were associated with undetectable levels and a 
high incidence of rejection, and the sirolimus dosage had to 
be switched very early to 15 mg preoperatively and 5 mg 
postoperatively to obtain detectable levels. The subsequent 
incidence of clinical rejection of 16%, and the incidence of 
steroid-resistant rejection of 4% seemed reasonable; how-
ever, the additional 12% incidence of subclinical acute 
rejection was worrisome. In the future, a short course of 
antibody induction might be preferable to allow for protec-
tion until adequate sirolimus levels are achieved. Implicit in 
this reasoning is the absolute need to have ready access to 
sirolimus levels if one is to use the agent in a rational 
manner. 
The opposing effects of tacrolimus and sirolimus on 
cholesterol were associated with reasonable cholesterol 
levels in our patients, although triglyceride levels tended to 
remain a bit elevated. Significant thrombocytopenia was 
relatively infrequent but did lead to sirolimus discontinua-
tion in 13% of the patients. 
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In summary, the combination of tacrolimus, sirolimus 
and steroids, without antibody induction, seemed to otfe; 
reasonable initial immunosuppressive safety and efficacy in 
renal transplant recipients. However, the lower initial dos-
ages of sirolimus were associated with undetectable levels 
and a high incidence of rejection. If one is to use tacrolimus 
and sirolimus in combination, high initial siroJimus dosages 
are necessary to achieve detectable levels. 
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